Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/25/2025 | $20.00 | Outperform | Leerink Partners |
| 6/20/2025 | Outperform | William Blair | |
| 10/22/2024 | $32.00 | Outperform | Robert W. Baird |
- PIPE-791 achieved high LPA1 brain receptor occupancy (RO) in healthy volunteers and progressive multiple sclerosis (PrMS) patients - PIPE-791 showed a safety and tolerability profile consistent with previous clinical studies - Topline data affirms planned doses for future Phase 2 clinical proof-of-concept trials Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced positive topline data from its PIPE-791 Phase 1b positron emission tomography (PET) trial. The trial met its primary objectives
Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the following investor conferences in September. Cantor Global Healthcare Conference 2025 – fireside chat on Thursday, September 4, 2025, at 9:10 a.m. ET. Morgan Stanley 23rd Annual Global Healthcare Conference – fireside chat on Monday, September 8, 2025, at 8:30 a.m. ET. Baird 2025 Global Healthcare Conference – fireside chat on Tuesday, September 9, 2025, at 2:00 p.m. ET. An audio webcast of t
- Topline data from the PIPE-307 Phase 2 VISTA trial for the treatment of relapsing-remitting multiple sclerosis (RRMS) is anticipated in the fourth quarter of 2025 - Initiation of a global Phase 2 proof-of-concept clinical trial of PIPE-791 in idiopathic pulmonary fibrosis (IPF) in the fourth quarter of 2025 - Cash runway projected to fund operations through 2027 Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its second-quarter 2025 financial results and updated its key clinical develop
4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
Leerink Partners initiated coverage of Contineum Therapeutics with a rating of Outperform and set a new price target of $20.00
William Blair initiated coverage of Contineum Therapeutics with a rating of Outperform
Robert W. Baird initiated coverage of Contineum Therapeutics with a rating of Outperform and set a new price target of $32.00
8-K - Contineum Therapeutics, Inc. (0001855175) (Filer)
SCHEDULE 13G/A - Contineum Therapeutics, Inc. (0001855175) (Subject)
10-Q - Contineum Therapeutics, Inc. (0001855175) (Filer)
Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D
Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Diego Miralles, M.D. as a member of its board of directors, effective March 14, 2025. "We are excited to welcome Diego to our board," commented Eef Schimmelpennink, Contineum's Chairperson. "He has successfully led the development of novel therapies throughout his distinguished career and has an extensive track record in both early stage research and all stages of clinical development. During his time at Janssen Research, Dr.
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a consultant for the company. "We are pleased to welcome Lori as chair of the board," said Brian Wong, M.D., Ph.D., President and CEO of RAPT. "In the four years that Lori has served as a board membe
SC 13G - Contineum Therapeutics, Inc. (0001855175) (Subject)